Biora Therapeutics Stock Extend Surge on FDA Feedback

Year-over-year, BIOR is down more than 86%

Digital Content Manager
Jan 11, 2023 at 10:12 AM
facebook twitter linkedin

Biora Therapeutics Inc (NASDAQ:BIOR) is looking to extend yesterday's pop, last seen up 8.5% at $5.86. This bull gap comes after the U.S. Food and Drug Administration (FDA) provided feedback for its program targeting ulcerative colitis, with the company saying that it is on track to file plans to initiate clinical trials in the second quarter. Plus, Wainwright raised its price target to $65 from $6.

The security is fresh off a Jan. 6, record low of $1.95, but yesterday closed above the 40-day moving average for the first time since August. The shares are today trading at their  highest level in more than one month. Year-over-year, though, BIOR Is down 86.8%.

Short sellers are already starting to hit the exits, with short interest down 9.4% in the last two reporting periods. Still the 11.73 million shares sold short account for 5.6% of BIOR's available float.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners